Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by deepoil0808on May 16, 2024 12:46pm
283 Views
Post# 36043700

Sure reads like a very disappointing press release

Sure reads like a very disappointing press releaseI think I am reading the tea leaves correctly and that the results will be inconclusive.

We learned more on the delay in enrollment.   They are having difficulty finding a homogenous group for their testing.   

This is concerning because I thought that their trials were addressed for everyone with a spinal injury, instead it is limited to a more homogenous group that already has evidence of some motor mobility before entering testing. 

So this is a very far cry from what I thought that it was and would apply to everyone who was paralyzed.   It is only for a select group and whom are not completely paralyzed.

Thought it would have been the Holy grail but it is clearly not.   Also read some concern for funding as they are now relieved that funds will last to Q3-2025.

I am definitely sitting this one out.    Will wait for trial results and then see how big the market is.   If you are targeting only a limited group, then market size is much smaller than boasted.  Could explain the changes in personnel and also why pr firm was needed with messaging. 

My personal opinion only

Good Luck, 


<< Previous
Bullboard Posts
Next >>